Saturday 17 October 2026
Export TSHA’s income statement to Excel — free account
Taysha Gene Therapies, Inc.
TSHA Healthcare Biotechnology
Taysha Gene Therapies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.8 million, up 17.3% from fiscal 2024. In the quarter to June 2026, revenue grew 206.8%, EPS fell 44.4%, free cash flow fell 100.3% and total debt rose 20.0%, each against the same quarter a year earlier.
3.62
0.11
−2.95%
Follow TSHA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | 0.00 | — | — |
P/S ratio |
— | 149.08 | — | — | |
P/FCF ratio |
— | 0.00 | — | — | |
P/Operating CF |
— | (65.80) | — | — | |
P/B ratio |
— | 7.12 | — | — | |
Price to Tangible BV |
— | 7.12 | — | — | |
EV/Sales |
— | 126.18 | — | — | |
EV/EBITDA |
— | 0.00 | — | — | |
EV/Operating CF |
— | (15.99) | — | — | |
EV/FCF |
— | (15.14) | — | — | |
Quick Ratio |
10.40 | 12.06 | 13.78 | 17.53 | |
Current Ratio |
10.48 | 12.23 | 14.04 | 17.76 | |
Net Debt/EBITDA |
7.32 | 9.65 | 5.28 | 8.63 | |
Debt/Assets |
16.06% | 14.59% | 16.30% | 10.47% | |
Debt/Equity |
0.23 | 0.20 | 0.23 | 0.13 | |
Asset Turnover |
0.00 | 0.05 | 0.00 | 0.00 | |
Operating CF/Net income |
0.74 | 0.96 | 0.96 | 0.87 | |
Capex/Depreciation |
(0.38) | (0.84) | (10.25) | 0.00 | |
Interest Coverage |
(2,268.27) | (2,358.33) | (4,831.78) | (7,891.50) | |
Research and Development Expense of Revenue |
0.00% | 454.91% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 161.04% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 64.34% | 0.00% | 0.00% | |
Graham Net Nets |
— | 0.13 | — | — | |
Graham Number |
— | 0.00 | — | — | |
Earnings Yield |
— | (6.18%) | — | — | |
Free Cash Flow Yield |
— | (5.59%) | — | — | |
Revenue per Share |
0.00 | 0.02 | 0.00 | 0.00 | |
Operating CF per Share |
(0.07) | (0.08) | (0.11) | (0.11) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.07) | (0.08) | (0.12) | (0.11) | |
Cash per Share |
0.84 | 1.00 | 0.76 | 1.23 | |
Shareholders Equity per Share |
0.62 | 0.77 | 0.58 | 1.05 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.62 | 0.77 | 0.58 | 1.05 | |
Free Cash Flow |
(24.27) | (26.97) | (43.90) | (40.42) | |
Working Capital |
271.32 | 298.10 | 262.15 | 435.46 | |
Capital Expenditures |
(0.11) | (0.25) | (3.02) | 0.00 | |
Net Current Asset Value |
202.39 | 228.27 | 193.84 | 378.27 | |
EV/EBIT |
— | 0.00 | — | — | |
Capex to Sales |
0.00 | 0.05 | 0.00 | 0.00 | |
Price to Operating Income |
— | 0.00 | — | — | |
| Other line items | |||||
Average Payables |
5.19 | 4.93 | 4.45 | 8.44 | |
Average Assets |
248.39 | 251.84 | 219.36 | 401.88 | |
Average Common Equity |
153.89 | 159.23 | 133.50 | 318.00 |
Columns are period end dates